UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

ResMed has convinced investors that a reduction in obesity rates globally thanks to GLP-1 drugs such as Ozempic will not necessarily reduce demand for its ventilators and machines, which improve ...

ResMed has beaten earnings forecasts in the second quarter due to higher sales of its sleep device products and masks despite fears that the take-up of weight-loss drugs would reduce demand as ...

This may also be called AutoBiPAP or even AutoVPAP, though ResMed’s current version is called AirCurve ... Finally, an AutoCPAP may be slightly more expensive than a standard CPAP machine, typically ...

It can also contribute to the risk of high blood pressure, heart disease, stroke, and other serious conditions. One way to treat sleep apnea is with a CPAP machine—a mask and hose that is worn over ...